Back to News
Market Impact: 0.1
Scancell FY26 Loss Widens; ISCIB1+ Phase 2 SCOPE Data Due In 2027
Source: Nasdaq
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Scancell Holdings plc, a clinical-stage biopharmaceutical company, reported preliminary unaudited financial results for the year ended April 30, 2026. The article provides no financial figures or performance details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Rising fuel costs slashed Delta’s profit outlook despite strong demand
- What's behind the recovery rally in tech stocks — plus, Elon Musk's very good week
- Wall Street Week | Michigan Manufacturing, AI Debt Investments, Baby Bonds, Canadian Coal Fight
- OpenAI's revenue scare, Delta earnings, what investors think of a Starbucks-Chipotle deal and more in Morning Squawk
- Tesla drops 'Full Self-Driving' brand name in Europe after regulator pushback
- Delta Air Lines cuts 2026 forecast on fuel surge, but CEO says demand is still strong
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Tools for Private Equity Due Diligence: A Buyer Workflow
- Weekly Update: In-App Tutorials, Futures Data, and Watchlist Enhancements